2,810 Johnson & Johnson $JNJ Shares Sold by SVB Wealth LLC

SVB Wealth LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 10.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 24,662 shares of the company’s stock after selling 2,810 shares during the quarter. SVB Wealth LLC’s holdings in Johnson & Johnson were worth $6,529,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the stock. Legacy Trust boosted its holdings in Johnson & Johnson by 3.5% in the 3rd quarter. Legacy Trust now owns 46,302 shares of the company’s stock worth $12,650,000 after buying an additional 1,549 shares during the last quarter. Warburton Capital Management LLC lifted its position in shares of Johnson & Johnson by 12.5% in the third quarter. Warburton Capital Management LLC now owns 1,132 shares of the company’s stock valued at $301,000 after acquiring an additional 126 shares in the last quarter. Coston McIsaac & Partners lifted its position in shares of Johnson & Johnson by 0.9% in the third quarter. Coston McIsaac & Partners now owns 38,526 shares of the company’s stock valued at $10,200,000 after acquiring an additional 356 shares in the last quarter. Tortoise Investment Management LLC boosted its stake in shares of Johnson & Johnson by 7.6% in the third quarter. Tortoise Investment Management LLC now owns 2,034 shares of the company’s stock worth $538,000 after acquiring an additional 144 shares during the last quarter. Finally, Everest Financial Group LLC boosted its stake in shares of Johnson & Johnson by 3.6% in the third quarter. Everest Financial Group LLC now owns 2,574 shares of the company’s stock worth $682,000 after acquiring an additional 89 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on JNJ shares. Wells Fargo & Company raised their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Scotiabank reaffirmed an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 29th. Bank of America restated a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.16% of the company’s stock.

More Johnson & Johnson News

Here’s some of the latest news about JNJ:

• Positive Sentiment: J&J reported favorable Phase 3 results for CAPLYTA in adults with bipolar I disorder, with the drug providing rapid relief of manic symptoms. Positive data could strengthen the case for expanding the medicine’s use and future sales. Johnson & Johnson Reports Favorable Data For Bipolar Study
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson
• Negative Sentiment: A Massachusetts jury awarded $3.3 million to the family of a woman who developed mesothelioma after using J&J talc-based baby powder. The award adds to ongoing talc-related litigation exposure. Massachusetts woman’s family awarded $3.3 million against Johnson & Johnson

Johnson & Johnson Price Performance

NYSE:JNJ opened at $283.69 on Friday. Johnson & Johnson has a 52 week low of $193.45 and a 52 week high of $286.08. The stock’s fifty day moving average is $266.83 and its two-hundred day moving average is $249.54. The company has a market capitalization of $682.93 billion, a P/E ratio of 42.98, a P/E/G ratio of 2.77 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the company posted $2.80 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.